Rindopepimut with Temodar Appears Promising in Newly Diagnosed Glioblastoma Multiforme (6/14/2010)
Maintenance therapy with rindopepimut (CDX-110) combined with Temodar® (temozolomide) resulted in a 70% progression-free rate at 5.5 months for newly diagnosed patients with glioblastoma multiforme (GBM). These findings were recently presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

Recurrent High-grade Glioma Patients May Benefit from Hypofractionated Stereotactic Radiation Therapy (6/1/2010)
Patients with recurrent, high-grade glioma who were treated with hypofractionated stereotactic radiation therapy (H-SRT) experienced minimal side effects and a median survival of 11 months. These results were recently published in the Journal of Clinical Oncology.

Link Between Cell Phone Use and Brain Tumors Remains Inconclusive (5/19/2010)
A large, international study has found no conclusive evidence that cell phone use increases the risk for brain tumors, according to an early online publication in the International Journal of Epidemiology.

Continuous Temodar Shows Promise Against Recurrent Glioma (4/1/2010)
Among patients with recurrent malignant glioma, treatment with continuous dose-intense Temodar® (temozolomide) shows promising safety and efficacy. The results of this Phase II clinical trial were published in the Journal of Clinical Oncology.

Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence (2/19/2010)
Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute.

More Brain and CNS Cancers - General News »